LONDON (Alliance News) - The following UK shares received analyst recommendations Tuesday morning and Monday:
----------
FTSE 100
----------
GOLDMAN RAISES EXPERIAN PRICE TARGET TO 985 (965) PENCE - 'SELL'
----------
SOCGEN RAISES GLAXOSMITHKLINE PRICE TARGET TO 1920 (1900) PENCE - 'BUY'
----------
FTSE 250
----------
NUMIS RAISES GREENE KING TO 'BUY' ('ADD') - TARGET 975 PENCE
----------
GOLDMAN CUTS GREENE KING PRICE TARGET TO 890 (910) PENCE - 'NEUTRAL'
----------
CANACCORD RAISES POLYMETAL PRICE TARGET TO 565 (540) PENCE - 'HOLD'
----------
CANACCORD RAISES KAZAKHMYS PRICE TARGET TO 300 (295) PENCE - 'HOLD'
----------
JPMORGAN RAISES HELLERMANNTYTON PRICE TARGET TO 380 (370) PENCE - 'OVERWEIGHT'
----------
GOLDMAN RAISES HELLERMANNTYTON PRICE TARGET TO 400 (390) PENCE - 'BUY'
----------
BERENBERG RAISES BODYCOTE PRICE TARGET TO 795 (776) PENCE - 'BUY'
----------
GOLDMAN CUTS RANK GROUP PRICE TARGET TO 162 (168) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS LADBROKES PRICE TARGET TO 110 (115) PENCE - 'SELL'
----------
GOLDMAN CUTS DE LA RUE PRICE TARGET TO 930 (970) PENCE - 'NEUTRAL'
----------
UBS CUTS SIG PRICE TARGET TO 220 (230) PENCE - 'BUY'
---------
MAIN MARKET AND AIM
----------
NUMIS RAISES PLEXUS HLDGS PLC TO 'BUY' ('ADD') - TARGET 372 (364) PENCE
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.
Zantac litigation fears overdone at GSK, says Shore Capital
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.
Read more